Page 8 - KIDNEY CANCER
P. 8
Results: Progression Free Survival Primary Endpoint
Cabozantinib significantly prolonged PFS relative to sunitinib (HR 0.60 (95%CI 0.37-0.97 [1-sided P-value=0.019])
